bioAffinity Technologies (NASDAQ:BIAF) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of bioAffinity Technologies (NASDAQ:BIAF) to a strong sell rating in a research report report published on Saturday morning.

bioAffinity Technologies Trading Up 3.8%

BIAF opened at $5.17 on Friday. The company has a current ratio of 0.64, a quick ratio of 0.63 and a debt-to-equity ratio of 0.27. The firm has a market cap of $5.07 million, a price-to-earnings ratio of -0.25 and a beta of 2.53. bioAffinity Technologies has a 12 month low of $4.02 and a 12 month high of $67.78. The stock has a fifty day moving average price of $8.22 and a 200-day moving average price of $9.96.

bioAffinity Technologies (NASDAQ:BIAF) last posted its earnings results on Thursday, August 14th. The company reported ($3.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.00) by ($0.90). The company had revenue of $1.27 million during the quarter, compared to analysts’ expectations of $1.51 million. bioAffinity Technologies had a negative net margin of 152.16% and a negative return on equity of 845.68%.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.